LISA CEBRUN MCCRAY: Open Payments
NPI 1740661719 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$487 in 9 payments from 8 companies in 2025. Trend: 2023 $138 · 2024 $604 · 2025 $487
Food & beverage: $392Education: $95
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $129 |
| JAZZ PHARMACEUTICALS INC. | 1 | $107 |
| SANOFI-AVENTIS U.S. LLC | 1 | $102 |
| Syndax Pharmaceuticals, Inc. | 1 | $33 |
| Janssen Biotech, Inc. | 1 | $33 |
| Incyte Corporation | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Gamida Cell Inc. | 1 | $24 |
Products named: RYLAZE, REZUROCK, Cresemba, DARZALEX, NIKTIMVO, LIVTENCITY, OMISIRGE.
Industry payments across TX — which companies pay providers there.
